MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1712)	10/24/2006 5:37:09 PM
From: Icebrg	Read Replies (1) of 1826

MGI Pharma downgraded to "sell" Tuesday, October 24, 2006 6:42:47 AM ET American Technology Research NEW YORK, October 24 (newratings.com) - Analyst Manoj K Garg of American Technology downgrades MGI Pharma Inc (MOGN.NAS) from "neutral" to "sell." The target price is set to $14. In a research note published yesterday, the analyst mentions that the company has reported robust 3Q06 earnings. The analyst adds, however, that MGI Pharma’s results are likely to deteriorate going ahead. While MGI Pharma’s core product, Aloxi, faces threats from generic Zofran, the company is expected to spend increasingly on R&D, which would exert pressure on the company’s profitability in 2007, American Technology says.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next